King Wealth Management Group’s Definium Therapeutics DFTX Stock Holding History

King Wealth Management Group’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$470K	Hold	10,000	–	–	0.05%	115
2026 Q1	$189K	Hold	10,000	–	–	0.02%	151
2025 Q4	$134K	Hold	10,000	–	–	0.02%	160
2025 Q3	$118K	Hold	10,000	–	–	0.01%	157
2025 Q2	$65K	Hold	10,000	–	–	0.01%	156
2025 Q1	$59K	Hold	10,000	–	–	0.01%	157
2024 Q4	$70K	Buy	+10,000	New	+$68.8K	0.01%	152

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

King Wealth Management Group's DFTX Position: Q2 2026 in Review

King Wealth Management Group held its Definium Therapeutics (DFTX) position steady in Q2 2026 at 10,000 shares worth $470K. The position accounts for 0.05% of the portfolio, ranked #115.

King Wealth Management Group first reported a position in DFTX in Q4 2024 and has held it in 7 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

King Wealth Management Group held 10,000 shares of Definium Therapeutics worth $470K as of Q2 2026.
King Wealth Management Group left its Definium Therapeutics share count unchanged in Q2 2026.
Definium Therapeutics made up 0.05% of King Wealth Management Group's portfolio in Q2 2026, its #115 holding.
King Wealth Management Group first reported a position in Definium Therapeutics in Q4 2024 and has held it in 7 quarters since.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on King Wealth Management Group's 13F filing for Q2 2026, filed 5 Aug 2026.